Company intelligence / Profile preview

Translatum Medicus Inc

Toronto, Ontario, Canadatranslatummedicus.com ↗

Ownership: Private
Development stage: Other

Overview

Translatum Medicus is developing a patented small molecule drug candidate (TMi-018) for dry AMD. The company leverages a translational platform that aligns preclinical markers with FDA-approved clinical trial endpoints. Their lead compound has demonstrated preclinical efficacy and is being reformulated from an investigational new drug previously shown to be safe in Phase II trials for non-eye indications. As of early 2025, the lead program is entering or in early Phase 1 clinical trials; no published human efficacy results yet.

Therapeutic areas: Ophthalmology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

Tracery

Clinical Stage

Indications: Geographic atrophy, Age-related macular degeneration

Beyond the preview

Go deeper on Translatum Medicus Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Translatum Medicus Inc.

Explore the full profile